Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk of Survival Events Over Time Between Young BRCA1/2 Carriers By Ogkologos - March 10, 2025 757 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR ‘Levelling Up’: What should it mean for cancer? February 2, 2022 FDA Approves Osimertinib for Locally Advanced, Unresectable Stage III Non-Small Cell... October 8, 2024 4-Year-Old Boy Calls Police To Tell Them About His Toys, Cop... October 31, 2021 Oncotype DX Breast Cancer Test May Be Less Accurate for Black... February 26, 2021 Load more HOT NEWS As More People with Cancer Use Medical Cannabis, Oncologists Face Questions... In memory of Dame Deborah James Poziotinib Shows Promise in EGFR and HER2 Exon 20 Mutated Non-Small... Biopsie: 5 lucruri pe care fiecare pacient trebuie să le cunoască